263 related articles for article (PubMed ID: 31936623)
1. Significance of 5-
Wakamatsu K; Fukushima S; Minagawa A; Omodaka T; Hida T; Hatta N; Takata M; Uhara H; Okuyama R; Ihn H
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936623
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
3. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
4. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
5. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
7. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
[TBL] [Abstract][Full Text] [Related]
8. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
11. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
13. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
[TBL] [Abstract][Full Text] [Related]
15. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
16. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
17. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.
Hasegawa M; Takata M; Hatta N; Wakamatsu K; Ito S; Takehara K
Melanoma Res; 1997 Jun; 7(3):243-51. PubMed ID: 9195564
[TBL] [Abstract][Full Text] [Related]
19. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
20. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]